After Regeneron, US Government Orders Additional COVID-19 Therapy From Eli Lilly

The U.S. government has announced to purchase additional doses of Eli Lilly And Co's LLY for its neutralizing antibody therapies for COVID-19.
Related Link: Distribution Resumes Of Eli Lilly COVID-19 Antibody Therapies.
As part of the agreement, Lilly will supply 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased by the U.S. government.
Approximately 200,000 doses will be shipped in Q3 2021, and the remaining to be shipped in Q4. This transaction is expected to generate approximately $330 million in revenue in the second half of 2021.
Bamlanivimab and etesevimab together are authorized under Emergency Use Authorization.
Read Next: Eli Lilly Under FDA Scrutiny At Its COVID-19 Drug Manufacturing Facilities Amid Staff Accusations.
The U.S. government also announced the purchase of additional doses of Regeneron Pharmaceuticals Inc's REGN COVID-19 antibody cocktail.
Price Action: LLY shares are up 0.03% at $233.17 during the premarket session on the last check Wednesday.

Overview Rating:

Speculative

100

0100